We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Hybrigenics Unveils a Lead Chemical Structure for Its Discovery of New Anticancer Drugs

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Hybrigenics Unveils a Lead Chemical Structure for Its Discovery of New Anticancer Drugs"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Hybrigenics (ALHYG), a bio-pharmaceutical company, announces the publication of a scientific article in Molecular Cancer Therapeutics showing the anticancer potential of HBX 41,108, its lead small molecule inhibitor of ubiquitin-specific protease no.7 (USP7).

Many cancer types from different organs are dependent on the crucial tumor-suppressor protein called p53, which is regulated by USP7. The article published in Molecular Cancer Therapeutics describes how Hybrigenics has demonstrated that small molecules can inhibit USP7 activity, resulting in the activation of functional p53 and in the growth inhibition of p53-dependent cancer cell lines.

HBX 41,108 is the lead compound of such USP7 inhibitors, with a demonstrated potential to become an innovative anticancer drug candidate after further chemical optimization.

Molecular Cancer Therapeutics is a highly-ranked international scientific journal accepting articles for publication after an academic peer-reviewed process with stringent acceptance criteria for novelty, relevance to the field and strength of experimental evidence.

"This publication highlights the recognition by the scientific community of our pioneer research position in the field of USP inhibition", said Frédéric Colland, Head of Biological Research at Hybrigenics.